Our verdict is Benign. Variant got -13 ACMG points: 0P and 13B. BP4_StrongBP6BS1BS2
The NM_001382.4(DPAGT1):c.729-4A>C variant causes a splice region, splice polypyrimidine tract, intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000415 in 1,614,024 control chromosomes in the GnomAD database, including 6 homozygotes. In-silico tool predicts a benign outcome for this variant. 3/3 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
DPAGT1 (HGNC:2995): (dolichyl-phosphate N-acetylglucosaminephosphotransferase 1) The protein encoded by this gene is an enzyme that catalyzes the first step in the dolichol-linked oligosaccharide pathway for glycoprotein biosynthesis. This enzyme belongs to the glycosyltransferase family 4. This protein is an integral membrane protein of the endoplasmic reticulum. The congenital disorder of glycosylation type Ij is caused by mutation in the gene encoding this enzyme. [provided by RefSeq, Jul 2008]
Computational evidence support a benign effect (BayesDel_noAF=-0.48).
BP6
Variant 11-119098047-T-G is Benign according to our data. Variant chr11-119098047-T-G is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 386275.We mark this variant Likely_benign, oryginal submissions are: {Likely_benign=2, Benign=1, Uncertain_significance=2}.
BS1
Variant frequency is greater than expected in population mid. gnomad4_exome allele frequency = 0.000416 (608/1461726) while in subpopulation MID AF= 0.00174 (10/5742). AF 95% confidence interval is 0.000944. There are 4 homozygotes in gnomad4_exome. There are 301 alleles in male gnomad4_exome subpopulation. Median coverage is 32. This position pass quality control queck.
Uncertain significance, criteria provided, single submitter
clinical testing
Ambry Genetics
May 24, 2021
The c.729-4A>C intronic alteration consists of a A to C substitution 4 nucleotides before coding exon 6 in the DPAGT1 gene. Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. -
DPAGT1-congenital disorder of glycosylation Uncertain:1
Uncertain significance, criteria provided, single submitter
clinical testing
Illumina Laboratory Services, Illumina
Apr 27, 2017
This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases did not allow this variant to be ruled in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. -
not specified Benign:1
Likely benign, criteria provided, single submitter
clinical testing
GeneDx
May 24, 2017
This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -
DPAGT1-related disorder Benign:1
Benign, no assertion criteria provided
clinical testing
PreventionGenetics, part of Exact Sciences
Sep 18, 2019
This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -
DPAGT1-congenital disorder of glycosylation;C3553645:Congenital myasthenic syndrome 13 Benign:1
Benign, criteria provided, single submitter
clinical testing
Labcorp Genetics (formerly Invitae), Labcorp
Jan 19, 2024
- -
not provided Benign:1
Likely benign, criteria provided, single submitter